PSAI segment decline pulls down Dr Reddy's Q1 show

Earnings were driven by one-off gains

Dr Reddy’s below than expected performance for the June quarter was led by a temporary disruption in the manufacturing of the active ingredient. Pharmaceutical services and Active Ingredients (PSAI) segment reported a 10 per cent decline in sales on a year-on-year basis and 33 per cent sequentially. The management, however, said that segments sales would normalize in the September quarter.

Global Generics sales grew 8 per cent year-on-year and 9 per cent sequentially. India and